9 results about "Emotional disorder" patented technology

The application discloses a use of a pharmaceutical composition of a phenolic acid compound and probiotics, and particularly relates to a combination of chlorogenic acid and lactobacillus reuteri. The combination of chlorogenic acid and lactobacillus reuteri can improve glycolipid metabolic disorder, improve cognitive dysfunction, emotional disorder and delay aging, and can be used for preparing a medicine for treating metabolic disorder combined with neuropsychiatric diseases.

The application discloses a polypeptide GRN-E and application thereof in preparation of a medicine or preparation for perimenopausal emotional disorder. It is found for the first time that a GRN-E fragment (a C-terminal domain of PGRN, an amino acid sequence is SEQ ID NO. 1 in a sequence listing) can pass through a blood-brain barrier and has a unique effect in relieving perimenopausal anxiety and depression. As a key functional fragment, the GRN-E has a more concentrated effect on a central nervous system and can effectively avoid off-target effects of a full-length protein. The polypeptide GRN-E of the application can be applied to preparation of a medicine or preparation for perimenopausal emotional disorder as an innovative treatment target and a novel biological preparation and has a high clinical conversion value.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

This invention discloses a full-spectrum emotion recognition system integrating biosignals and behavioral features, belonging to the field of emotion recognition technology. The system includes the following steps: S1, data acquisition; S2, data preprocessing; S3, emotion feature fusion; S4, emotion analysis and output; S5, full-spectrum adaptation. This full-spectrum emotion recognition system integrates biosignals and behavioral features to achieve full-spectrum emotion recognition, ranging from common emotional distress to severe emotional disorders. By integrating multi-dimensional data of biosignals and behavioral features, and based on scientific classification standards, it accurately distinguishes children with different degrees of emotional problems, allowing each group to receive appropriate intervention. This precise classification avoids the blindness of intervention measures, providing basic regulatory support for children with common emotional distress and securing timely intervention opportunities for children with severe emotional disorders. It comprehensively meets the emotional management needs of different children and promotes their healthy emotional development.

The application discloses application of MRS2578 in preparation of a medicine for preventing or treating depression and belongs to the field of medicines. The CAS registration number of the MRS2578 is 711019-86-2. The application discloses a new application of MRS2578, i.e. the application of the compound in preparation of a medicine for preventing or treating depression. Experimental researches show that after the MRS2578 is given, the sucrose preference degree of model mice is improved to a certain extent, and the emotional disorder behavior of the model mice is significantly reduced. Based on the above pharmacological results, the technical scheme provided by the application has a good clinical popularization and application prospect.

The application belongs to the technical field of pharmaceutical preparations, and specifically discloses an acetyl gastrodin transdermal patch and a preparation method thereof. The transdermal patch takes acetyl gastrodin as an effective component, is encapsulated in cubic phase liposomes composed of glycerol monostearate, cholesterol and Pluronic F127, is dispersed in a complex matrix of hydroxypropyl methyl cellulose and ethyl cellulose, and is matched with a complex transdermal enhancer of glyceryl caprylate / caprate and ethanol. In the preparation, the liposome material is first melted to load the drug, and then drug-loaded cubic phase liposomes are formed through ice water bath ultrasonic treatment. Then, the drug-loaded cubic phase liposomes are mixed with the polymer matrix and excipients, are defoamed, are coated, and are dried in two steps to be shaped. The cubic phase liposomes are used to significantly improve the drug penetration rate and stability, realize 24-hour smooth drug release, efficiently penetrate the skin and the blood-brain barrier, significantly inhibit non-small cell lung cancer brain metastases, improve tumor secondary anxiety and depression, have excellent skin compatibility, and provide a new non-invasive synergistic treatment scheme for brain tumors and concurrent emotional disorders.

The application discloses a target strategy and a drug intervention method for improving Primrose syndrome, and belongs to the technical field of biological medicine. The experiment proves that Momordin Ic can significantly improve the SUMO level of ZBTB20 in vitro cells or Primrose syndrome (PS) mice, can effectively improve the defects of reduced neuron dendritic branching in the hippocampal CA1 region of the PS mice in pathology, can enhance the complexity, and can improve the cognitive and emotional disorders such as memory impairment and anxiety-like behavior of the PS mice to different degrees in behavior. The application discloses that Momordin Ic can improve the PS-related neuropathological changes and behavioral cognitive defects by targeting the SENP1-ZBTB20-SUMO pathway, and provides a new candidate molecule and a clear action target for developing potential therapeutic drugs for Primrose syndrome.

This invention discloses a method and system for intervening in adolescent mood disorders based on Up-Adjustment Motivation State (UP-A). The intervention method includes: configuring core training tasks and constructing an intervention framework; setting initial intervention strategies for users and initiating the first week of intervention training; periodically collecting multi-dimensional motivation-related data from users; constructing an early warning indicator system and conducting risk monitoring based on the multi-dimensional motivation-related data; initiating an early warning response procedure if a risk is detected, and continuing intervention training if no risk is detected; calculating the user's current motivation level based on the multi-dimensional motivation-related data and classifying the user into subtypes; matching corresponding intervention strategies from a predefined intervention strategy matrix according to the user's current motivation level and subtype, and mobilizing an AI intervention module and / or a manual intervention module to execute the intervention strategy, thereby providing personalized intervention for users based on the intervention framework. This effectively improves user compliance and overall treatment effectiveness.

The present invention relates to an extract of algae of the genus Ulva and its use in human and animal nutrition for the treatment of inflammation, preferably inflammation associated with metabolic syndrome, as well as for the treatment of cognitive and / or emotional disorders induced by metabolic syndrome. The present invention also relates to food supplements and food compositions comprising an extract of algae of the genus Ulva.